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Platinum-based chemotherapy is the primary treatment for human ovarian cancer. Overcoming
platinum resistance has become a critical issue in the current chemotherapeutic strategies of ovarian
cancer as drug resistance is the main reason for treatment failure. Cytotoxic gold compounds hold
great promise to reach this goal; however, their modes of action are still largely unknown. To shed
light on the underlying molecular mechanisms, we performed 2-DE and MS analysis to identify
differential protein expression in a cisplatin-resistant human ovarian cancer cell line (A2780/R)
following treatment with two representative gold compounds, namely Auranofin and Auoxo6. It is
shown that Auranofin mainly acts by altering the expression of Proteasome proteins while Auoxo6
mostly modifies proteins related to mRNA splicing, trafficking and stability. We also found that
Thioredoxin-like protein 1 expression is greatly reduced after treatment with both gold compounds.
These results are highly indicative of the likely sites of action of the two tested gold drugs and of
the affected cellular functions. The implications of the obtained results are thoroughly discussed in
the frame of current knowledge on cytotoxic gold agents.
Introduction
Ovarian cancer is the second among gynecological cancers in
number of new cases and the first among gynecological cancers
in rate of deaths in Western countries.1,2
Platinum-based chemotherapy, such as cisplatin, is the primary
treatment for human ovarian cancer. The occurrence of intrinsic
or acquired tumor chemoresistance remains themajor determinant
of chemotherapy failure and an unfavorable clinical outcome.3,4
Several mechanisms have been implicated in the development
of tumor drug resistance.4–7
Owing to the great clinical success of cisplatin, several new
platinum and non-platinummetal compounds have been prepared,
characterized and evaluated pharmacologically as anticancer
agents.8 In recent years, research has increasingly focused on
cytotoxic gold compounds as drug candidates.9 Gold(III) complexes
display the same electronic configuration (d8) and similar
structural and reactivity features of platinum(II) complexes10
but the respective mechanisms appear to be radically different.
Remarkably, a number of gold(III) complexes have been found
to possess promising pharmacological profiles in vitro and
some of them also in vivo.11,12
Previous studies have shown that cytotoxic gold(III) compounds
are able to induce cell death through apoptosis,13,14 essentially
triggered by a direct mitochondrial damage.15,16
Proteomic profiling offers an excellent opportunity for the
identification of proteins that mediate apoptotic pathways when
cells are treated with cytotoxic agents.17 Themolecular mechanisms
of anticancer metallodrugs are usually very complicated and varied
owing to the high reactivity of these compounds toward
biomolecules, to their being (in most cases) prodrugs (thus under-
going large chemical transformations and extensive speciation
within the biological milieu) and to the large differences in the
electronic structure and reactivity existing among the various metal
centers. Yim et al. examined protein expression in cisplatin-treated
HeLa cervical carcinoma cells and found 21 altered proteins.18
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These authors showed that cisplatin induced a marked down-
regulation of nuclear factor kB. Yao et al. carried out comparative
proteomic studies of colon cancer cells in response to oxaliplatin
treatment and highlighted a number of proteins that were simulta-
neously altered in three distinct colon cancer cell lines.19 These
proteins were identified and found to take part in many cellular
processes, such as apoptosis, signal transduction, transcription and
translation, cell structural organization, andmetabolism. Che et al.
used 2D electrophoresis based proteomic technology to investigate
the protein expression profiles of human nasopharyngeal carci-
noma SUNE1 cells upon treatment with gold(III) porphyrin 1a.20
Relevant changes in the expression of a number of proteins
engaged in redox metabolism and in the mitochondrial functions
were detected suggesting that mitochondria could be a primary
target for gold(III) porphyrin 1a.
In our previous work we analyzed proteomic alterations
induced by Auranofin and Auoxo6 in a human ovarian cancer
cisplatin-sensitive cell line (A2780/S).21 Six altered proteins were in
common between the two treatments. Some of the affected
proteins are primarily involved in intracellular redox homeostasis,
implying that cell damage is probably the consequence of severe
oxidative stress. Here we report the results of a proteomic study on
the cellular effects of both gold compounds, Auranofin and
Auoxo6 (Fig. 1), on A2780/R (cisplatin-resistant) cancer cells.
From our analysis it emerges that the two different gold
compounds cause different proteomic modifications. Auranofin
mainly acts by altering the expression of Proteasome apparatus
proteins, while Auoxo6 by an expression modification of proteins
related to mRNA splicing, trafficking and stability. Furthermore
we found that a protein whose expression is reduced after cells
treatment with both gold compounds is Thioredoxin-like protein
1, involved in oxidative stress defence.
Experimental procedures
Materials and reagents
Auoxo6 was synthesized as described in ref. 22, and Auranofin was
obtained from Vinci Biochem. All other chemicals were of
analytical grade. RPMI 1640 cell culture medium, fetal calf serum
(FCS), and phosphate-buffered saline were obtained from Celbio
(Milan, Italy); sulforhodamine B (SRB) was obtained from Sigma
(Milan, Italy).
Cell lines
For cytotoxicity studies the cisplatin-sensitive human ovarian
carcinoma cell line (A2780/S) and its cisplatin-resistant cell
subline (A2780/R) were used. For proteomic studies the
A2780/R subline was used. Cell lines were maintained in
RPMI1640 medium supplemented with 10% of FCS and
antibiotics at 37 1C in a 5% CO2 atmosphere and subcultured
twice weekly.
Cell growth inhibition studies
The cytotoxic effects of Auranofin and Auoxo6 were evaluated
against the A2780/S and the A2780/R cell lines according to
the procedure described by Skehan.23 Auoxo6 was diluted in
DMSO and Auranofin in ethanol as stock solutions (10 mM).
Exponentially growing cells were seeded in 96-well microplates
at a density of 5  103 cell per well. After cell inoculation,
the microtitre plates were incubated under standard culture
conditions (37 1C, 5% CO2, 95% air and 100% relative
humidity) for 24 h prior to the addition of study compounds.
After 24 h, the medium was removed and replaced with fresh
medium containing drug concentrations ranging from 0.003 to
100 mM for a continuous exposure of 72 h for both compounds
tested. For comparison purposes the cytotoxic effects of
cisplatin, measured under the same experimental conditions,
were also determined. Then the cells were fixed with 100 mL of
ice-cold 10% trichloroacetic acid (TCA) for 60 min at 4 1C,
rinsed 6 times with water and air-dried. Fixed cells were
stained with 50 mL of sulforhodamine B (SRB) solution
(0.4% SRB/0.1% acetic acid), rinsed with 0.1% acetic acid
and air-dried. At the end of the staining period, SRB was
dissolved in 150 mL of 10 mM Tris–HCl solution (pH 10.5) for
10 min in a gyratory shaker. Optical density was read in a
microplate reader interfaced with the software Microplate
Manager/PV version 4.0 (Bio-Rad Laboratories, Milan, Italy)
at 540 nm. The IC50 drug concentration resulting in a 50%
reduction in the net protein content (as measured by SRB
staining) in drug-treated cells as compared to untreated control
cells was determined after 72 h of drug exposure. The IC50 data
represent the mean of at least three independent experiments.
Sample preparation and 2D gel electrophoresis
Cells were seeded in tissue-culture plates at 5  104 cells mL1
(total volume 30 mL) and incubated overnight, then exposed to
concentrations of the study compounds equal to 72 h-exposure
IC50 values for 24 h. At the end of incubation cells were washed
with phosphate-buffered saline, then were scraped in RIPA
buffer [50 mM Tris–HCl, pH 7.0, 1% NP-40, 150 mM NaCl,
2 mM ethylene glycol bis(2-aminoethyl ether)tetraacetic acid,
100 mM NaF] containing a cocktail of protease inhibitors
(Sigma). Cells were sonicated (10 s) and protein extracts were
clarified by centrifugation at 8000g for 10 min. Proteins were
precipitated following a chloroform/methanol protocol24 and
pellets were resuspended in 8 M urea, 4% 3-[(3-cholamido-
propyl)dimethylammonio]propanesulfonic acid (CHAPS) and
20 mM dithiothreitol (DTT). Three independent experiments
were performed and each sample was run in triplicate to assess
biological and analytical variations. Isoelectrofocusing (first
dimension) was carried out on nonlinear wide-range immobilized
pH gradients (IPGs; pH 3.0–10; 18 cm-long IPG strips; GE
Healthcare, Uppsala, Sweden) using an EttanTM IPGphort
system (GE Healthcare, Uppsala, Sweden). Analytical-run IPG
strips were rehydrated with 60 mg of total proteins in 350 mL of
lysis buffer and 0.2% carrier ampholyte for 1 h at 0 V and for 8 h
Fig. 1 Auranofin (A) and Auoxo6 (B).
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at 30 V, at 20 1C. The strips were focused at 20 1C according to
the following electrical conditions: 200 V for 1 h, from 300 to
3500 V in 30 min, 3500 V for 3 h, from 3500 to 8000 V in 30 min,
and 8000 V until a total of 80000 V h1 was reached. For
preparative gels, 18 cm IPG strips (pH 3–10 NL) were rehydrated
overnight for 20 h at room temperature in 350 mL of rehydration
buffer containing 8 M urea, 2% w/v CHAPS, 0.5% DTT, and
0.5% IPG buffer with the same pH range as the Immobiline
DryStrips and a trace of bromophenol blue. Rehydrated strips
were rinsed in double-distilled water to remove urea crystals.
Samples (up to 1 mg) were cup-loaded near the anode of the IPG
strips using an Ettan IPGphor cup-loading manifold (GE
Healthcare) according to the manufacturer’s protocol. After
focusing, analytical and preparative IPG strips were equilibrated
for 12 min in 6 M urea, 30% glycerol, 2% sodium dodecyl
sulfate, 2% DTT in 0.05 M Tris–HCl buffer, pH 6.8, and
subsequently for 5 min in the same urea/sodium dodecyl
sulfate/Tris–HCl buffer solution where DTT was substituted
with 2.5% iodoacetamide. The second dimension was carried out
on 9–16% polyacrylamide linear gradient gels (18 cm  20 cm 
1.5 mm) at 10 1C and 40 mA per gel constant current until the
dye front reached the bottom of the gel. Analytical gels were
stained with ammoniacal silver nitrate as previously described;25
MS-preparative gels were stained with colloidal Coomassie.26
Image analysis and statistics
Gel images were acquired with an Epson expression 1680 PRO
scanner. For each condition, three biological replicates were
performed and only spots present in all the replicates were
taken into consideration for subsequent analysis. Computer-aided
2D image analysis was carried out using ImageMaster 2D
Platinum version 6.0 (GE Healthcare). Relative spot volume
(%V= 100  V single spot/V all spots, where V= integrated
OD over the spot area) was used for quantitative analysis in
order to reduce experimental errors. The normalized intensity
of spots on three replicates of 2D gel was averaged and
standard deviation was calculated for each condition. The mean
values were compared among the three different conditions
(control cells, Auranofin-treated cells and Auoxo6-treated cells)
by analysis of variance followed by a two-tailed non-paired
Student’s t-test with ORIGIN 7.5 (Microcal Software, Inc.).
P o 0.05 was considered statistically significant.
Protein identification by mass spectrometry
Protein identification was carried out by peptide mass finger-
printing on an Ettan matrix-assisted laser desorption/ioniza-
tion (MALDI) time of flight (TOF) Pro mass spectrometer
(Amersham Biosciences), as previously described.27 Spots,
visualized by a colloidal Coomassie staining protocol, were
manually excised, destained and acetonitrile-dehydrated.
Successively, they were rehydrated in trypsin solution and
in-gel protein digestion was performed by overnight incubation
at 37 1C. From each excised spot, 0.75 mL of recovered digested
peptides were prepared for MALDI-TOFMS by spotting them
onto the MALDI target, allowing them to dry and then mixing
them with 0.75 mL of matrix solution [saturated solution of
a-cyano-4-hydroxycinnamic acid in 50% (v/v) acetonitrile and
0.5% (v/v) trifluoroacetic acid]. After application of the matrix
to the dried sample and drying, tryptic peptide masses were
acquired. Mass-fingerprinting searching was carried out in the
NCBInr and Swiss-Prot databases using Mascot (Matrix
Science, London, UK, http://www.matrixscience.com). Protein
identification was achieved on the basis of corresponding
experimental and theoretical peptide-fingerprinting patterns.
A mass tolerance of 100 ppm was allowed and only one missed
cleavage site accepted. Alkylation of cysteine by carbamido-
methylation was assumed as a fixed modification, whereas
oxidation of methionine was considered a possible modification.
Criteria used to accept identifications included the extent of
sequence coverage, the number of matched peptides and a
probabilistic score, as reported in Table 2. Tryptic digests that
did not produceMALDI-TOF unambiguous identifications were
subsequently acidified with 2 mL of a 1% trifluoroacetic acid
solution, and then subjected to electrospray ionization (ESI)–ion
trap MS/MS peptide sequencing using an LCQ DECA ion trap
mass spectrometer (Thermo Finnigan, San Jose, CA, USA).
With the use of ZIP-TIPTM pipette tips for sample preparation
(Millipore, Billerica, MA, USA), previously equilibrated in 50%
acetonitrile solution and abundantly washed in 0.1% trifluoro-
acetic acid, acidified samples were enriched. Tryptic peptide
elution from the ZIP-TIPTM matrix was achieved with a 70%
methanol and 0.5% formic acid solution, and 3 mL of such
concentrated sample solutions were then loaded in the nanospray
needle. MS/MS database searching was performed by Turbo-
SEQUEST (Thermo) and Mascot MS/MS ion search software
(www.matrixscience.com) in the Swiss-Prot/TrEMBL or NCBInr
databases. Following criteria were applied: MS accuracy:1.2 Da,
MS/MS mass accuracy: 0.6 Da, peptide precursor charge: 2+,
monoisotopic experimental mass values, trypsin digestion with one
allowed missed cleavage, fixed carbamidomethylation of cysteines
and variable oxidation of methionine.
Western blotting analysis of proteomic candidates
Cells conditions were the same as those of the 2-D experiments.
Samples (30 mg) were separated by 12% SDS-PAGE and
transferred onto a PVDF membrane (Millipore). To confirm
the results obtained from 2-D analysis, the relative amount of the
Transitional endoplasmic reticulum ATPase (TERA) (spot 17)
and the Hypoxia up-regulated protein 1 (HYOU1) (spot 7)
was assessed by Western blot with appropriate monoclonal
antibodies (Santa Cruz Biotechnology). According to datasheets
both antibodies were employed with a 1 : 1000 dilution in 2%
milk. For quantification, blots were stained with Coomassie
brilliant blue R-250 and subjected to densitometric analysis
performed using Quantity One Software (Bio-Rad). Statistical
analysis of the data was performed by Student’s t-test; p-values
o0.05 were considered statistically significant. The intensity of
the immunostained bands was normalized with the total protein
intensities measured by Coomassie brilliant blue R-250 from
the same blot.
Results
Cell growth inhibition was measured, according to the procedure
of Skehan,23 after 72 h exposure to the compounds. As expected
on the basis of our previous results,11,21 both compounds showed
relevant cytotoxic activity, with IC50 values typically falling in
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the low mM range (Table 1). In addition, both study compounds
turned out to be more active than cisplatin against both the
cisplatin-sensitive cell line and the resistant one with cross-
resistance ratios (r) markedly lower (i.e. 0.94 and 2.5 for
Auranofin and Auoxo6, respectively) than that of cisplatin
(17.4) (Table 1). We observed that very limited cell death is
evident, for both compounds, at 24 h, this rendering a classical
proteomic approach well feasible.28
To analyze in detail protein expression modifications induced
by the two drugs, proteomic analyses of A2780/R treated and
untreated cells were performed. Representative 2D Coomassie-
stained gels for control (panel C), Auoxo6-treated (panel A) and
Auranofin-treated (panel B) A2780/R cells are shown in Fig. 2.
An average of about 1300 protein spots was separated on each
gel. To obtain statistically significant results, each sample was
run in triplicate. Remarkably, both Auranofin and Auoxo6
treatments caused small modifications of protein expression
profiles. Only a limited number of protein spots manifested
appreciable down- or up-regulation. When gels corresponding
to untreated cells were used as a reference in gel analysis,
the density of 38 spots was found to change significantly after
both treatments. Spots with at least a 1.5-fold (P o 0.05)
change in their expression level were considered as ‘‘signifi-
cantly changed’’. Comparative analysis revealed that 18 spots
were differentially expressed in cells treated with Auranofin; of
these, 7 spots resulted to be up-regulated and 11 down-
regulated. We found 20 spots differentially expressed in
Auoxo6-treated cells: 7 up and 13 down-expressed. The locations
of these protein spots are marked with circles in the representa-
tive gel shown in Fig. 2. Among these 38 differences excised from
preparative Coomassie-stained 2-DE gels, in gel digested with
trypsin and analyzed by mass spectrometry, we were able to
identify 30 proteins. Not all spots could be identified because of
the relatively low protein concentrations and MS sensitivity
limitations. Positions of the identified spots are indicated by
circles and numbers in the representative gels shown in Fig. 2. A
list of the up- and down-regulated proteins is given in Table 2.
The table reports all the identified proteins, their relative
amounts including protein name, NCBI database accession
number, Mascot score, peptide matched, sequence coverage
and statistical analysis (fold change Z 1.5 and p-valueo 0.05).
A group of 10 protein spots (6, 7, 13, 8, 16, 11, 14, 17, 19 and 20)
shows a significant down-expression in cells treated with
Auranofin versus controls. A protein spot (15) shows an
increase of the intensity level with a p-value of 0.037. The
volume of 12 protein spots (19, 23, 25, 37, 26, 27, 32, 29, 33, 36,
38 and 34) was significantly down-regulated in the Auoxo6-treated
cells with a p-value ranging between 0.05 and 0.005
when compared with the control group. Four protein spots
(31, 24, 22 and 35) showed a significant volume increase in
Auoxo6-treated cells.
Among the identified protein spots we found as down-
expressed in both treatments the Thioredoxin-like protein 1
(TXL-1) (spot 19), involved in the regulation of cell redox
homeostasis. In Auranofin-treated cells this protein resulted to
Table 1 In vitro antiproliferative activity of Auranofin and Auoxo6
against A2780 ovarian carcinoma human cell lines, either sensitive
(A2780/S) or resistant (A2780/R) to cisplatin
A2780/S, IC50 (mM)  DS A2780/R, IC50 (mM)  DS
Auoxo6
Mean 2.4  0.5 6.0  0.5
R 2.5
Auranofin
Mean 0.50  0.10 0.47  0.06
R 0.94
Cisplatin
Mean 1.50.4 26.10.1
R 17.4
The experiments were performed in triplicate; r, cross-resistance ratios;
DS, standard deviation.
Fig. 2 Representative 2D gel images for: (A) A2780 Auranofin-treated cells, (B) A2780 Auoxo6-treated cells and (C) A2780 control cells. Circles
indicate differentially expressed spots. Numbers indicate proteins identified by MS (see Table 2).
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be reduced in expression with a p-value ofo0.005; in Auoxo6-
treated cells the corresponding p-value was o0.05. Fig. 3
shows the relative amounts and statistical analysis for this
protein in Auranofin-treated and Auoxo6-treated cells versus
control cells. In Fig. 3 are also shown magnified regions from
triplicate 2D gel images with this spot.
Altered proteins upon Auranofin treatment
Among proteins identified as down-regulated after treatment
with Auranofin we found phosphoribosylformylglycinamidine
synthase, a protein involved in purine metabolism (spot 6),
Hypoxia up-regulated protein 1 (HYOU1) (spot 7), that belongs
to the heat shock protein 70 family and has a pivotal role in
cytoprotective cellular mechanisms triggered by oxygen depriva-
tion. This protein may play a role as a molecular chaperone and
participate in protein folding. We have noticed a down expression
of the 26S protease regulatory subunit 8 (spot 8), a protein
involved in the ATP-dependent degradation of ubiquitinated
proteins. Two proteins with an ATP-dependent proteolytic
activity: the proteasome subunit alpha (spot 13) and beta (spot 16)
type-6, belonging to a multi-catalytic proteinase complex which is
characterized by its ability to cleave peptides with Arg, Phe, Tyr,
Leu and Glu adjacent to the leaving group. The subunit beta is
responsible for the peptidyl glutamyl-like activity.
Moreover resulted down expressed: the RNA polymerases
I and III subunit RPAC1(spot 14) which catalyzes the
Table 2 Relative protein expression changes of Auranofin-treated cells vs. control cells and Auoxo6-treated cells vs. control cells. ND: Not
Detected. Bold numbers indicate the spot changed after both treatments
Spot no. Protein name ACa Scoreb
No. of
matching
peptidesc
Sequence
coveraged
(%)
%V (104) mean 
(SD)e
Fold
changef
P valueControl Treatment
Control/
treatment
Spots decreased following Auranofin treatment
6 Phosphoribosylformylglycinamidine
synthase
O15067 118 14 13 502  122 275  119 1.83 o0.01
7 Hypoxia up-regulated protein 1 Q9Y4L1 134 11 15 457  81 291  109 1.57 o0.05
13 Proteasome subunit alpha type-6 P60900 119 8 33 428  178 240  96 1.79 o0.05
8 26S protease regulatory subunit 8 P62195 147 13 36 775  210 518  67 1.50 o0.05
16 Proteasome subunit beta type-6 P28072 119 7 32 671  210 367  231 1.83 o0.05
11 Nucleoporin p54 Q7Z3B4 104 8 25 243  54 163  56 1.49 o0.05
14 DNA-directed RNA polymerases
I and III subunit RPAC1
O15160 101 7 28 631  278 342  81 1.84 o0.05
17 Transitional endoplasmic reticulum
ATPase
P55072 182 19 31 253  98 162  23 1.56 o0.05
20 Actin, cytoplasmic 1 P60709 109 10 34 8031  3922 3984  2006 2.02 o0.05
19 Thioredoxin-like protein 1 O43396 153 11 54 503  80 142  99 3.52 o0.001
Spots increased following Auranofin treatment
15 NADP-dependent malic enzyme +
T-complex protein 1 subunit alpha
P48163 +
P17987
83 + 73 9 + 9 23 + 17 164  61 319  146 0.51 o0.05
Spots decreased following Auoxo6 treatment
23 Aldehyde dehydrogenase
X mitochondrial + RuvB-like 1
P30837 +
Q9Y265
158 + 91 14 + 9 33 + 28 363  29 207  77 1.75 o0.005
25 DnaJ homolog subfamily B member 1 P25685 185 16 43 813  161 531  135 1.53 o0.01
37 Keratin, type I cytoskeletal 9 P35527 81 8 21 308  116 187  43 1.65 o0.05
26 Keratin, type II cytoskeletal 6B P04259 100 8 17 160  92 ND ND o0.005
27 Plasminogen activator inhibitor 1
RNA-binding protein
Q8NC51 124 14 29 3461  426 2283  901 1.52 o0.05
32 Glyceraldehyde-3-phosphate
dehydrogenase
P04406 115 10 32 2610  729 1531  763 1.70 o0.05
29 Far upstream element-binding
protein 2
Q92945 150 13 25 179  46 114  35 1.57 o0.05
33 Splicing factor 3B subunit 4 Q15427 109 9 31 784  248 480  156 1.63 o0.05
36 Splicing factor 1 Q15637 92 8 14 531  147 274  114 1.93 o0.01
38 Elongation factor 2 P13639 113 14 19 265  46 158  99 1.67 o0.05
34 Heat shock protein 105 kDa + actin,
cytoplasmic 2
Q92598 +
P63261
157 + 88 18+9 26 + 29 345  116 184  47 1.88 o0.05
19 Thioredoxin-like protein 1 O43396 153 11 54 503  80 276  28 1.82 o0.05
Spots increased following Auoxo6 treatment
31 T-complex protein 1 subunit theta P50990 110 8 22 123  32 220  36 0.56 o0.01
24 Tubulin alpha-1A chain o 1B Q71U36 +
P68363
86 9 35 358  69 564  126 0.64 o0.05
22 Serine/arginine-rich splicing factor 9 Q13242 117 9 36 27  78 255  78 0.10 o0.005
35 Ornithine aminotransferase.
Mitochondrial
P04181 104 7 24 90  20 228  69 0.39 o0.005
a Swiss-Prot/TrEMBL accession number. b MASCOTscore (Matrix Science, London, UK; http://www.matrixscience.com). c Number of peptide
masses matching the top hit from Ms-Fit PMF. d Percentage of amino acid sequence coverage of matched peptides in the identified proteins.
e Each value represents the mean and SD of individually computed %V (V = integration of OD over the spot area; %V = V single spot/V total
spots) in three different gels of control, Auranofin and Auoxo6. f Fold change (control vs. Auranofin and control vs. Auoxo6) was calculated
dividing %V from control by the %V from Auranofin and from Auoxo6.
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transcription of DNA into RNA; the cytoplasmic Actin (spot 20),
involved in various types of cell motility and ubiquitously
expressed in all eukaryotic cells, the Nucleoporin p54 (spot 11),
a component of the nuclear pore complex, required for the
trafficking across the nuclear membrane and Transitional
endoplasmic reticulum ATPase (TERA) (spot 17), involved
in protein folding.
In one spot (spot 15) showing a significant positive correlation
with Auranofin treatment we found two proteins: the NADP-
dependent malic enzyme, that generates NADPH for fatty acid
biosynthesis and a molecular chaperone, the T-complex protein 1
subunit alpha. The activity of the first enzyme links the glycolytic
and citric acid cycles; the second protein assists the folding of
proteins upon ATP hydrolysis. Moreover, this protein is known
to play a role, in vitro, in folding of actin and tubulin.
Altered proteins upon Auoxo6 treatment
Fifteen protein spots were significantly correlated with Auoxo6
treatment; these proteins are listed in Table 2. Eleven spots
showed negative correlation while four spots showed positive
correlation with treatment. Significant negative correlations
were found concerning spot 23, identified as the mitochondrial
aldehyde dehydrogenase X, with traces of RuvB-like 1 protein.
This mitochondrial protein plays a major role in the detoxification
of alcohol-derived acetaldehyde. The second protein is
involved in transcriptional activation of selected genes by
nucleosomal histone acetylation. This complex seems to be
required for the activation of transcriptional programs
associated with oncogenes and proto-oncogenes. We found,
as down-expressed, a protein that interacts with HSP70 and
can stimulate its ATPase activity: this protein is the DnaJ
homolog subfamily B member 1 (spot 25). Two cytoskeletal
Keratins, type I (spot 37) and type II (spot 26), were also
observed to be down expressed.
Two proteins related to mRNA resulted as down-expressed:
the plasminogen activator inhibitor 1 RNA-binding protein
(spot 27) and the far upstream element-binding protein 2
(spot 29). These two proteins play a role in the regulation of
mRNA stability and in mRNA trafficking respectively. Other
proteins showing the same trend are two splicing factors: splicing
factor 3B subunit 4 (spot 33) and splicing factor 1 (spot 36). Also,
an elongation factor 2 (spot 38), a heat shock protein 105 kDa
and the cytoplasmic Actin 2 (both in the same spot 34) revealed a
similar trend. The glyceraldehyde-3-phosphate dehydrogenase
(spot 32) playing a role in glycolysis and nuclear functions
resulted to be reduced in expression after treatment. It partici-
pates in nuclear events including transcription, RNA transport,
DNA replication and apoptosis.
Fig. 3 Magnified regions of 2D gel images indicating spot 19, corresponding to Thioredoxin-like protein 1. In the column on the right the relative
histogram is reported. Black bars, white bars and gray bars represent control, Auranofin and Auoxo6 treatment, respectively. Bars represent
the mean  the standard deviation of spot volume percentage from three different experiments. The volume percentage is calculated as V single
spot/V total spots (V is the integration of the optical density over the spot area). Asterisks indicate statistically significant differences with Po 0.05
(*) and P o 0.001 (**).
Fig. 4 Validation of proteomic results by western blot analysis. Western blot was probed with antibodies against TERA and HYOU1, proteins
identified by proteomic screening. The intensity of immunostained bands was normalized with the total protein intensities measured from the same
blot stained with Coomassie brilliant blue (in panel A and panel B a representative band of the lane is reported). Auranofin treatment induced a
decrease of expression of TERA (A) and HYOU1 (B) after 24 h. (C) Histograms representing TERA and HYOU1 protein expression variation.
Bars represent the mean  the standard deviation of western blot signals from three different experiments, expressed as arbitrary units. Black bars
represent control cells, grey bars represent Auranofin-treated cells and white bars represent Auoxo6-treated cells. Asterisk indicates that the
difference is statistically significant, P o 0.05. The two-tailed non-paired Student’s t-test was performed using ORIGIN 6.0 (p o 0.05).
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Among proteins whose expression showed a positive correla-
tion with Auoxo6 treatment, we identified a molecular chaperone
which assists protein folding, the T-complex protein 1 subunit
theta (spot 31); the major constituent of microtubules, protein
tubulin alpha-1A chain (spot 24), a protein involved in splicing,
the serine/arginine-rich splicing factor 9 (spot 22) and a
mitochondrial protein involved in amino-acid biosynthesis,
ornithine aminotransferase (spot 35).
To validate the obtained results, as well as to further
evaluate the nature and importance of some of the identified
proteins that changed expression after drug treatment, mono-
dimensional (1D) western blotting analyses were performed.
For these analyses, a new experiment was performed on
A2780/R cells either untreated or treated for 24 h with
Auranofin and Auoxo6. Two proteins, TERA (spot 17) and
HYOU1 (spot 7), were validated by western blotting. As
shown in Fig. 4, TERA and HYOU1 are both down-expressed
in Auranofin-treated cells. The protein expression-fold changes
are consistent with the reported 2-D results.
Discussion
Our previous proteomic study reporting the effects of Auranofin
and Auoxo6 on A2780 cisplatin-sensitive cells21 indicated that
Auranofin and Auoxo6 have a similar mode of action. The
protein pattern modifications induced by both gold compounds
on those cells were limited; notably, some of the affected
proteins were in common and were involved in redox home-
ostasis and induction of apoptosis. In the present paper we
extended that kind of investigation to the parent cell line
resistant to cisplatin (A2780/R) to highlight the mechanisms
of action of these two representative gold compounds in
overcoming platinum-based drug resistance. As reported in
Table 1, Auranofin and Auoxo6 manifest different cytotoxic
properties versus A2780/S and A2780/R cells. In particular,
Auranofin shows roughly the same cytotoxic activity in both
cell lines (r = 0.94), while Auoxo6 is more active in sensitive
cells compared to resistant ones (r = 2.4). This different
behaviour could be somehow related to the different proteomic
profiles observed in our experiments. It is noteworthy that both
treatments, though causing extensive cell death at 72 h, induce
very limited proteome changes at 24 h. The affected proteins
that were later identified participate in a variety of cellular
processes, such as cell structural organization, defence against
oxidative stress, transcription and protein degradation. Inter-
estingly, we found that Auranofin reduced the amount of
HYOU1, a molecular chaperone involved in protein folding.
This protein has a protective role in cells because it contributes
to apoptosis suppression under hypoxic conditions.29 Miyagi
et al. showed that tumorigenicity is reduced in prostate cancer
by decreasing HYOU1 expression.30 Namba et al. reported that
up-regulation of HYOU1 in cancer cells can inhibit apoptosis.31
We may assume that HYOU1 correlates with chemotherapeutic
resistance and that gold compounds could overcome drug resis-
tance by decreasing expression levels of apoptotic suppressors. We
also found that Auranofin decreases the expression of proteasome
subunits. These proteins are responsible for protein degradation.
The ubiquitin/proteasome pathway is indeed the primary system
for extralysosomal protein degradation, necessary for maintaining
normal cellular functions. In recent years, inhibitors of the
proteasome were suggested as novel antitumor agents in
cancer therapy.32 Tumor cells are in fact more susceptible
than normal cells to these inhibitors because of the burden
placed on the proteasome due to the increased extent of
damaged proteins under stress conditions.33 Notably, it was
previously reported by many authors that proteasome inhibi-
tors trigger apoptosis. Moreover, Auranofin treatment, under
our experimental conditions, reduces the amount of TERA, a
protein necessary for the export of misfolded proteins from
endoplasmic reticulum. Overall, modification of the protein
degradation pathway and the inhibition of the expression of
the proteasomal ex apparatus could be associated with apop-
totic cancer cell death induced by this drug. As far as the
effects of Auoxo6 are concerned, we discovered a reduced
expression in proteins related to mRNA transcription, stabi-
lity, trafficking and splicing. Among them far upstream
element-binding protein 2 (FUBP2), which is known to be
over-expressed in tumor cells together with FUBP1,34 plays a
role in mRNA trafficking and splicing. This over expression
supports tumor cells proliferation and migration. In contrast,
its reduced expression level, found in our experiments, could
be responsible for the cytotoxic effects of Auoxo6 on A2780
cells. We also found a reduced expression of cytoskeletal
proteins. Multiple evidence suggests that cells use cytoskeleton
dynamic state as an indicator of cellular health. Many authors
showed that reorganization of cytoskeletal proteins correlates
with apoptosis induction35,36 and it is known that ROS are
involved in remodeling the actin cytoskeleton.37,38 Among the
most significant proteins involved in cytoskeletal reorganiza-
tion we identified cytoplasmic Actin and two types of
Keratins.39 We found a down-regulation of two isoforms of
Actin: actin 1 or beta-actin after Auranofin treatment and actin
2 or gamma-actin after Auoxo6 treatment, suggesting that
these gold compounds may act by a mechanism involving
remodeling of the cytoskeleton and alteration of the cell shape,
which could lead to an apoptotic death. Furthermore, we
found a protein whose expression level is strongly reduced
after both treatments: this protein is TXL-1; it is involved in
cell redox homeostasis.40 Oxidative stress is characterized by
the depletion of the general antioxidant systems leading to an
alteration of the cellular redox status. Thus, the balance
between reactive oxygen species production and antioxidants
determines the degree of oxidative stress.41 Thioredoxins have
emerged as an essential family of proteins directly related to
the antioxidant cellular network.42 We observed a significant
two-fold down expression of this protein after both treat-
ments; this fact could be related to the cytotoxicity of these
gold compounds. We know that cancer cells exist in a stressed
environment and rely on the Trxs for protection against stress-
disregulated redox signaling. By triggering a reduction in
expression of a protein with important antioxidant functions
gold compounds could determine massive oxidative stress that
eventually leads to cellular death.
Moreover the proteomic approach could be useful to under-
stand the resistance mechanisms involved in platinum resis-
tance as reported by Yan et al.43 They identified five proteins
to become candidates for platinum resistance and useful for
further study of screening of resistant biomarkers.
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Conclusions
Proteomics methods have the potential to provide specific insight
into the alterations induced by drugs on protein expression. In
turn, the observed proteomic alterations may be related to the
modes of action of the drugs themselves. We have used such an
approach to investigate the molecular mechanisms through
which two cytotoxic gold based drugs i.e. Auranofin and Auoxo6
cause their biological effects. Notably, highly different proteomic
alterations were detected for the two investigated metallodrugs
suggesting a substantially different mechanism of action. It is
found that Auranofin mostly acts by altering the amount of
proteasome proteins while Auoxo6 mainly modifies proteins
related to mRNA splicing, trafficking and stability. However,
we also observed that a protein involved in oxidative stress
defence, i.e. Thioredoxin-like protein 1, is greatly reduced after
treatment with both gold compounds. Our proteomic results
suggest the putative targets of these compounds. Extending the
analysis to the transcription level will better explain if the
observed differences in protein amounts are caused by transcrip-
tional or post-transcriptional events. Overall, these findings may
contribute to elucidate the molecular mechanisms of the tested
drugs and offer insight into their respective modes and sites of
biological action.
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